Treatment with thymic extract TFX for chronic active hepatitis B. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment with thymic extract TFX for chronic active hepatitis B.

Arch Immunol Ther Exp (Warsz). 1991;39(5-6):537-47. Unique Identifier : AIDSLINE MED/93038038
Dworniak D; Tchorzewski H; Pokoca L; Tkacz B; Drobnik S; Baj Z; Luciak M; Clinic of Infectious Disease, Military Medical Academy, Lodz.

Abstract: Eighteen patients with biopsy-proven chronic active hepatitis B (CAHB) and a significantly lowered CD4+/CD8+ cell number ratio were treated with thymic factor X (TFX): group I (n = 12) - for 12 months, group II (n = 6) for 6 months. As early as 14 days after starting the treatment a lowering of CD8+ cell numbers with a rise in CD4+/CD8+ cell number ratio were found. These changes continued to progress during the next months and were accompanied by decreased in NK cell numbers with enhancement of NK cell activity. Normalization of the biochemical and immunological parameters occurred after 5-6 months of the treatment. In both groups of patients seroconversion in the HBe system was observed after 9-12 months of the treatment. After two years complete clinical remission persists with normal biochemical and immunological findings and without reversion in the HBe system. The results seem to indicate that TFX has an immunostimulatory action and exerts beneficial effects on the course of CAHB.
Keywords: Adolescence Adult CD4-CD8 Ratio Female Hepatitis B/*DRUG THERAPY/IMMUNOLOGY Hepatitis B Antibodies/BLOOD Hepatitis B Surface Antigens/BLOOD Hepatitis, Chronic Active/*DRUG THERAPY/IMMUNOLOGY Human Immunoglobulins/BLOOD Killer Cells, Natural/IMMUNOLOGY Male Middle Age Thymus Extracts/*THERAPEUTIC USE JOURNAL ARTICLEKWDadolescenceadultcd4-cd8ratiofemalehepatitisb/KWDdrugtherapy/immunologyhepatitisbantibodies/bloodhepatitisbsurfaceantigens/bloodhepatitis,chronicactive/KWDdrugtherapy/immunologyhumanimmunoglobulins/bloodkillercells,natural/immunologymalemiddleagethymusextracts/KWDtherapeuticusejournalarticle
930130
M9311136

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .